CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth.
Huynh T, Murray J, Flemming CL, Kamili A, Hofmann U, Cheung L, Roundhill EA, Yu DMT, Webber HT, Schwab M, Henderson MJ, Haber M, Norris MD, Fletcher JI.
Huynh T, et al. Among authors: roundhill ea.
Biochem Pharmacol. 2020 Feb;172:113770. doi: 10.1016/j.bcp.2019.113770. Epub 2019 Dec 17.
Biochem Pharmacol. 2020.
PMID: 31862449